Neurobiology of Aging
Volume 29, Issue 5 , Pages 669-675 , May 2008

CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease

  • Niki S.M. Schoonenboom

      Affiliations

    • Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author at: Department of Neurology, Alzheimer Center, VU University Medical Center, Postbus 7057, 1081 HV Amsterdam, The Netherlands. Tel.: +31 204440183/646022014; fax: +31 204440715.
    • ,
  • Wiesje M. van der Flier

      Affiliations

    • Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    • ,
  • Marinus A. Blankenstein

      Affiliations

    • Department of Clinical Chemistry, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    • ,
  • Femke H. Bouwman

      Affiliations

    • Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    • ,
  • Gerard J. Van Kamp

      Affiliations

    • Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    • ,
  • Frederik Barkhof

      Affiliations

    • Department of Radiology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    • ,
  • Philip Scheltens

      Affiliations

    • Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands

Received 12 May 2006 ,Revised 17 November 2006 ,Accepted 25 November 2006.

References 

  1. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 1999;56:673–680
  2. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2:605–613
  3. Bobinski M, De Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience. 2000;95:721–725
  4. Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol. Aging. 2007;28:1070–1074
  5. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch. Neurol. 2003;60:1696–1702
  6. Consensus Report of the Working Group on: “molecular and biochemical markers of Alzheimer's disease”, 1998. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 19, 109–116.
  7. Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, et al. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis. Assoc. Disord. 2004;18:190–195
  8. De Leon MJ, De Santi S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease. J. Int. Med. 2004;256:205–223
  9. De Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging. 2006;27:394–401
  10. Folstein MF, Robins LN, Helzer JE. The mini-mental state examination. Arch. Gen. Psychiatry. 1983;40:812
  11. Frisoni GB, Testa C, Sabatolli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J. Neurol. Neurosurg. Psychiatry. 2005;76:112–114
  12. Galton CJ, Pattersen K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging, and pathological study of 13 cases. Brain. 2000;123:484–498
  13. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology. 2002;58:1476–1482
  14. Hampel H, Buerger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol. 2005;62:770–773
  15. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 1999;52:1555–1562
  16. Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann. Neurol. 2005;58:748–757
  17. Jack CR, Dickson DW, Parisi JW, Xu YC, Cha RH, O’Brien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58:750–757
  18. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 1998;44:17–26
  19. Kemp PM, Holmes C, Hoffmann SM, Bolt L, Holmes R, Rowden J, et al. Alzheimer's disease: differences in technetium-99m HMPAO SPECT scan findings between early onset and late onset dementia. J. Neurol. Neurosurg. Psychiatry. 2003;74:715–719
  20. Korf ESC, Wahlund LO, Visser PJ, Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 2004;63:94–100
  21. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J. Neurol. Neurosurg. Psychiatry. 2002;73:126–133
  22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  23. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 2001;58:1395–1402
  24. Rusinek H, Endo Y, De Santi S, Frid D, Tsui WH, Segal S, et al. Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology. 2004;63:2354–2359
  25. Schonknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig M, et al. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Res. 2003;120:231–238
  26. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, et al. Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology. 2004;62:1580–1584
  27. Schoonenboom SN, Visser PJ, Mulder C, Lindeboom J, Van Elk EJ, Van Kamp GJ, et al. Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase. 2005;11:8–13
  28. Schroder J, Pantel J, Ida N, Essig M, Hartmann T, Knopp MV, et al. Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol. Psychiatry. 1997;2:505–507
  29. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology. 2003;61:487–492
  30. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652–656
  31. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psychiatry. 1999;46:750–755
  32. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 1993;61:1828–1834
  33. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245–258
  34. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000;285:49–52
  35. Vermersch P, Leys D, Scheltens P, Barkhof F. Visual rating of hippocampal atrophy: correlation with volumetry. J. Neurol. Neurosurg. Psychiatry. 1994;57:1015
  36. Wahlund LO, Julin P, Johansson SE, Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J. Neurol. Neurosurg. Psychiatry. 2000;69:630–635
  37. Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci. Lett. 2003;339:99–102

PII: S0197-4580(06)00440-4

doi: 10.1016/j.neurobiolaging.2006.11.018

Neurobiology of Aging
Volume 29, Issue 5 , Pages 669-675 , May 2008

Article Tools

* Image Usage & Resolution